Pharmafile Logo

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

- PMLiVE

As we move forward in 2024, the healthcare industry has embraced the idea that AI-generated synthetic patients are here for the long haul. The remarkable ability to utilize artificial patients that mimic real-world patient data addresses crucial unmet needs, making it nearly impossible to envision a future healthcare industry without widespread usage and integration of synthetic patients.

However, we must strike a delicate balance between integrating AI tools into market research and acknowledging the invaluable role of human intelligence in understanding, verifying, supervising and analysing insights. In this article, we delve into the compelling arguments surrounding the opportunities and risks associated with the utilization of AI-generated synthetic patients in healthcare market research.

Read the full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Pharma & life sciences division growth allows Pegasus to fill three new senior positions

Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Infographic: The vaccine opportunity in Asia

As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...

Webinar: What next for biosimilars?

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST

Understanding the Patient Journey

The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme.  Technology...

Case Study: Oncology diagnostic biomarker landscaping study

The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...